Senexin A

Senexin A is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters[1][2].

Product Specifications

CAS Number

[1366002-50-7]

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319, H332

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Senexin_A.html

Purity

99.79

Solubility

DMSO : ≥ 100 mg/mL

Smiles

N#CC1=CC=C2C(C(NCCC3=CC=CC=C3)=NC=N2)=C1

Molecular Formula

C17H14N4

Molecular Weight

274.32

Precautions

H302, H312, H315, H319, H332

References & Citations

[1]Porter DC, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21;109 (34) :13799-804.|[2]Ho TY, et al. The study of a novel CDK8 inhibitor E966-0530-45418 that inhibits prostate cancer metastasis in vitro and in vivo. Biomed Pharmacother. 2023 Jun;162:114667.